Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

sulindac sulfone

Known as: (Z)-5-Fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic Acid, Exisulind 
An inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac. After oral administration, sulindac undergoes extensive… Expand
National Institutes of Health

Related topics

Related topics

9 relations

Broader (4)

Anticarcinogenic AgentsAntineoplastic AgentsCyclooxygenase InhibitorsSulindac

Narrower (3)

AptosynCP248FGN-1
analogs & derivativescarboplatin/exisulind/gemcitabine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
Regression of Mouse Prostatic Intraepithelial Neoplasia by Nonsteroidal Anti-inflammatory Drugs in the Transgenic Adenocarcinoma Mouse Prostate Model
Purpose: Epidemiologic studies have revealed a decreased risk of colon cancer among people who have regularly taken… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2003
Highly Cited
2003
Cyclooxygenase-independent Induction of Apoptosis by Sulindac Sulfone Is Mediated by Polyamines in Colon Cancer*
Sulindac, a non-steroidal anti-inflammatory prodrug, is metabolized into pharmacologically active sulfide and sulfone derivatives… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2001
Highly Cited
2001
Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy.
PURPOSE We evaluated the safety and efficacy of exisulind for delaying disease progression in men with increasing prostate… Expand
Highly Cited
2001
Highly Cited
2001
Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.
Exisulind (Aptosyn) is a novel antineoplastic drug being developed for the prevention and treatment of precancerous and malignant… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2000
Highly Cited
2000
Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin.
Sulindac sulfone (exisulind), although a nonsteroidal anti-inflammatory drug derivative, induces apoptosis in tumor cells by a… Expand
Highly Cited
1999
Highly Cited
1999
Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis.
OBJECTIVES Recent studies have shown that Exisulind, a sulfone metabolite of the nonsteroidal anti-inflammatory drug (NSAID… Expand
Highly Cited
1999
Highly Cited
1999
Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines.
We examined the activity of two metabolites of sulindac (a nonsteroidal anti-inflammatory drug), sulindac sulfide and sulindac… Expand
Highly Cited
1999
Highly Cited
1999
Sulindac inhibits activation of the NF-kappaB pathway.
Sulindac is a non-steroidal anti-inflammatory agent that is related both structurally and pharmacologically to indomethacin. In… Expand
Highly Cited
1997
Highly Cited
1997
Sulfone metabolite of sulindac inhibits mammary carcinogenesis.
Sulindac sulfoxide, a commonly prescribed anti-inflammatory drug, has cancer chemopreventive activity. During its metabolism, the… Expand
Highly Cited
1997
Highly Cited
1997
Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels.
Nonsteroidal anti-inflammatory drugs (NSAIDs), such as sulindac, have cancer chemopreventive properties by a mechanism that has… Expand
  • figure I
  • figure 2
  • table 1
  • table 2
  • table 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE